KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) EPS (Weighted Average and Diluted) (2016 - 2025)

Emergent BioSolutions' EPS (Weighted Average and Diluted) history spans 16 years, with the latest figure at -$0.96 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 68.42% year-over-year to -$0.96; the TTM value through Dec 2025 reached $0.92, up 124.73%, while the annual FY2025 figure was $0.93, 125.83% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.96 in Q4 2025 per EBS's latest filing, down from $0.91 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.6 in Q4 2021 to a low of -$5.38 in Q2 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.89, with a median of -$0.66 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 612.5% in 2021, then plummeted 10500.0% in 2022.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $3.6 in 2021, then plummeted by 137.22% to -$1.34 in 2022, then skyrocketed by 34.33% to -$0.88 in 2023, then surged by 35.23% to -$0.57 in 2024, then crashed by 68.42% to -$0.96 in 2025.
  • Per Business Quant, the three most recent readings for EBS's EPS (Weighted Average and Diluted) are -$0.96 (Q4 2025), $0.91 (Q3 2025), and -$0.22 (Q2 2025).